CLINICAL & PIPELINE·Drug Approval
Celltrion's Avtozma (Tocilizumab-anoh) Biosimilar Gains FDA BLA Approval, Signaling Market Shift
Celltrion Inc. has secured FDA approval for AVTOZMA (tocilizumab-anoh), a biosimilar to the Interleukin-6 receptor antagonist tocilizumab, under BLA761498, effective January 21, 2026. This approval introduces a new competitive option in the inflammatory and autoimmune disease market, offering intravenous and subcutaneous formulations. Procurement directors and supply chain VPs should assess AVTOZMA for cost efficiencies and supply diversification, impacting market dynamics significantly.
90-Day Activity